Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2004-05-27
2008-11-11
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S130100, C424S133100, C424S141100, C424S142100, C424S143100, C530S387900, C530S388100, C530S388150, C530S388220, C530S389100
Reexamination Certificate
active
07449185
ABSTRACT:
The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4710457 (1987-12-01), Dupont et al.
patent: 4710473 (1987-12-01), Morris
patent: 4959314 (1990-09-01), Mark et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5393739 (1995-02-01), Bentz et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5457035 (1995-10-01), Baum et al.
patent: 5578569 (1996-11-01), Tam
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5599708 (1997-02-01), Mundy et al.
patent: 5623053 (1997-04-01), Gastinel et al.
patent: 5658756 (1997-08-01), Rodan et al.
patent: 5843678 (1998-12-01), Boyle
patent: 5843901 (1998-12-01), Roeske
patent: 5985832 (1999-11-01), Roodman et al.
patent: 6015938 (2000-01-01), Boyle et al.
patent: 6017729 (2000-01-01), Anderson et al.
patent: 6087555 (2000-07-01), Dunstan et al.
patent: 6242213 (2001-06-01), Anderson
patent: 6242586 (2001-06-01), Gorman et al.
patent: 6271349 (2001-08-01), Dougall et al.
patent: 6284485 (2001-09-01), Boyle et al.
patent: 6284728 (2001-09-01), Boyle et al.
patent: 6284740 (2001-09-01), Boyle et al.
patent: 6288032 (2001-09-01), Boyle et al.
patent: 6316408 (2001-11-01), Boyle
patent: 6369027 (2002-04-01), Boyle et al.
patent: 6419929 (2002-07-01), Anderson
patent: 6525180 (2003-02-01), Gorman et al.
patent: 6528482 (2003-03-01), Anderson et al.
patent: 6537763 (2003-03-01), Dougall et al.
patent: 6562948 (2003-05-01), Anderson
patent: 6569430 (2003-05-01), Waldmann et al.
patent: 6649164 (2003-11-01), Maraskovsky
patent: 6740522 (2004-05-01), Anderson et al.
patent: 7097834 (2006-08-01), Boyle
patent: 2002/0081720 (2002-06-01), Dougall et al.
patent: 2002/0086826 (2002-07-01), Anderson et al.
patent: 2002/0086827 (2002-07-01), Anderson
patent: 2002/0127637 (2002-09-01), Ni et al.
patent: 2002/0150989 (2002-10-01), Greene et al.
patent: 2002/0169117 (2002-11-01), Maraskovsky
patent: 2003/0100069 (2003-05-01), Ni et al.
patent: 2003/0100488 (2003-05-01), Boyle
patent: 2003/0103978 (2003-06-01), Deshpande et al.
patent: 2003/0104485 (2003-06-01), Boyle
patent: 2003/0144480 (2003-07-01), Gorman et al.
patent: 2003/0166097 (2003-09-01), Greene et al.
patent: 2003/0175840 (2003-09-01), Anderson et al.
patent: 2004/0023313 (2004-02-01), Boyle et al.
patent: 2004/0033535 (2004-02-01), Boyle et al.
patent: 56180/98 (1998-07-01), None
patent: 68518/98 (1998-11-01), None
patent: 71205/98 (1998-11-01), None
patent: 0514130 (1992-11-01), None
patent: 0514130 (1992-11-01), None
patent: 0 526 905 (1993-02-01), None
patent: 0 526 905 (1993-02-01), None
patent: 0727211 (1996-08-01), None
patent: 0874045 (1998-10-01), None
patent: 0911342 (1999-04-01), None
patent: 330400 (1999-05-01), None
patent: 86/00922 (1986-02-01), None
patent: 90/14363 (1990-11-01), None
patent: 93/12227 (1993-06-01), None
patent: 93/21946 (1993-11-01), None
patent: 95/11308 (1995-04-01), None
patent: 96/26217 (1996-08-01), None
patent: 96/28546 (1996-09-01), None
patent: 97/00317 (1997-01-01), None
patent: 97/00318 (1997-01-01), None
patent: 97/23614 (1997-07-01), None
patent: 98/07840 (1998-02-01), None
patent: 98/25958 (1998-06-01), None
patent: 98/28246 (1998-07-01), None
patent: 98/28424 (1998-07-01), None
patent: 98/28426 (1998-07-01), None
patent: 98/46644 (1998-10-01), None
patent: 98/46751 (1998-10-01), None
patent: 98/49305 (1998-11-01), None
patent: 98/54201 (1998-12-01), None
patent: 99/19468 (1999-04-01), None
patent: 99/53942 (1999-10-01), None
patent: 99/58674 (1999-11-01), None
patent: 99/58674 (1999-11-01), None
patent: 01 03719 (2001-01-01), None
patent: 01 03719 (2001-01-01), None
patent: 01 17543 (2001-03-01), None
patent: 01 17543 (2001-03-01), None
patent: 01 18203 (2001-03-01), None
patent: 03002713 (2003-01-01), None
Benjamini et al., eds., Immunology: A Short Course, 2nd edition, Wiley-Liss, New York, p. 40.
Burgess, T.C., et al., “The ligand for osteoprotegrin (OPGL) directly activates mature osteoclasts.”J. Cell Biol., 145:527-38 (1999).
Chambers, T.J., “Regulation of the differentiation and function of osteoclasts.”J. Pathol. 192:4-13 (2000).
Fata, J.E., et al., “The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development.”Cell103:41-50 (2000).
Faust, J., et al., “Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors.”J. Cell Biochem. 72:67-80 (1999).
Fuller, K., et al., “Trance is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.”J. Exp. Med., 188:997-1001 (Sep. 7, 1998).
Gao, Y.H., et al., “Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF).”Biochem. Biophys. Res. Commun. 252:697-702 (1998).
Greenfield, E.M., et al., “Regulation of osteoclast activity.”Life Sci. 65:1087-102 (1999).
Hsu, H., et al., “Tumor necrosis factor receptor family member Rank mediates osteoclast differentiation and activation induced by osteoprotegrin ligand.”Proc. Natl. Acad. Sci. USA96:3540-5 (1999).
Itonaga, I., et al., “Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegrin ligand-dependent.”J. Pathol. 192:97-104 (2000).
Kim, D., et al., “Regulation of peripheral lymph node genesis by the tumor necrosis factor family member Trance.”J. Exp. Med. 192:1467-78 (2000).
Kim, Nacksung, et al., “Diverse roles of the tumor necrosis factor family member Trance in skeletal physiology revealed by Trance deficiency and partial rescue by a lymphocyte-expressed Trance transgene.”Proc. Natl. Acad. Sci. USA97:10905-10 (2000).
Kinpara, K., et al., “Osteoclast differentiation factor in human osteosarcoma cell line.”J. Immunoassay21:327-40 (2000).
Kitazawa, R., et al., “Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene.”Biochim. Biophys. Acta1445:134-41 (1999).
Kong, Y.Y., et al., “Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegrin ligand.”Nature402:304-9 (1999).
Kong, Y.Y. and J.M. Penninger, “Molecular control of bone remodeling and osteoporosis.”Exp. Gerontol. 35:947-56 (2000).
Lacey et al., “Osteoprotegrin ligand is a cytokine that regulates osteoclast differentiation and activation”,Cell93:165-76 (Apr. 17, 1998).
Lacey et al., “Osteoprotegrin ligand modulates murine osteoclast survival in vitro and in vivo.”Am J Pathol. 157:435-48 (2000).
Nakagawa, N., et al., “Rank is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.”Biochem. Biophys. Res. Commun. 253:395-400 (1998).
O'Brien, E.A., et al., “Osteoprotegrin ligand regulates osteoclast adherence to the bone surface in mouse calvaria.”Biochem. Biophys. Res. Commun. 274:281-90 (2000).
Oyajobi et al., “Therapeutic efficacy of a soluble receptor activator of nuclear factor kappa-B-IgG Fc Fusion Protein in
Goto Masaaki
Higashio Kanji
Kinosaki Masahiko
Kobayashi Fumie
Morinaga Tomonori
Daiichi Sankyo Company, Limited
Kemmerer Elizabeth C.
Knobbe Martens Olson & Bear LLP
LandOfFree
Antibodies to OCIF-binding molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to OCIF-binding molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to OCIF-binding molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4041142